title: Administration of carnosine in the treatment of acute spinal cord injury.
abstract: L-Carnosine is an endogenously synthesized dipeptide composed of beta-alanine and L-histidine. It acts as a free radical scavenger and possesses antioxidant properties. L-Carnosine reduces proinflammatory and profibrotic cytokines such as transforming growth factor-beta (TGF-beta), interleukin (IL)-1, and tumor necrosis factor (TNF)-alpha in different experimental settings. In the present study, we investigated the efficacy of L and D-carnosine on the animal model of spinal cord injury (SCI). The spinal cord was exposed via a four-level T5-T8 laminectomy and SCI was produced by extradural compression of the spinal cord at level T6-T7 using an aneurysm clip with a closing force of 24 g. Treatment with D-carnosine (150 mg/kg administered i.p., 1 h and 6h, after SCI), but not L-carnosine significantly decreased (a) the degree of spinal cord inflammation and tissue injury (histological score), (b) neutrophil infiltration (myeloperoxidase activity), (c) nitrotyrosine formation, inducible NO synthase (iNOS) and Hsp70 expression, (d) proinflammatory cytokines, and (e) apoptosis (TUNEL staining, Fas ligand, Bax, and Bcl-2 expression). Furthermore, D-carnosine (150 mg/kg administered i.p., 1 h and 6 h, after SCI) significantly ameliorated the loss of limb function (evaluated by motor recovery score). Taken together, our results demonstrate the strong difference between L-carnosine and D-carnosine. The result strongly suggests that D-carnosine treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.
authors.affiliation: IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo C.Da Casazza, 98100 Messina, Italy. dipaolar@unime.it
authors.forename: Rosanna
authors.initials: R
authors.lastname: Di Paola
authors.forename: Daniela
authors.initials: D
authors.lastname: Impellizzeri
authors.forename: Angela Trovato
authors.initials: AT
authors.lastname: Salinaro
authors.forename: Emanuela
authors.initials: E
authors.lastname: Mazzon
authors.forename: Francesco
authors.initials: F
authors.lastname: Bellia
authors.forename: Monia
authors.initials: M
authors.lastname: Cavallaro
authors.forename: Carolin
authors.initials: C
authors.lastname: Cornelius
authors.forename: Graziella
authors.initials: G
authors.lastname: Vecchio
authors.forename: Vittorio
authors.initials: V
authors.lastname: Calabrese
authors.forename: Enrico
authors.initials: E
authors.lastname: Rizzarelli
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cuzzocrea
mesh_terms: D000818:Animals; D002336:Carnosine / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D053222:Fas Ligand Protein / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D008297:Male; D051379:Mice; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D013119:Spinal Cord Injuries / Q000188:drug therapy*; D014443:Tyrosine / Q000031:analogs & derivatives / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D053222:Fas Ligand Protein; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; C002744:3-nitrotyrosine; D014443:Tyrosine; D002336:Carnosine